VECURONIUM BROMIDE FOR INJECTION POWDER FOR SOLUTION

Country: Canada

Language: English

Source: Health Canada

Active ingredient:

VECURONIUM BROMIDE

Available from:

PHARMACEUTICAL PARTNERS OF CANADA INC

ATC code:

M03AC03

INN (International Name):

VECURONIUM

Dosage:

10MG

Pharmaceutical form:

POWDER FOR SOLUTION

Composition:

VECURONIUM BROMIDE 10MG

Administration route:

INTRAVENOUS

Units in package:

10ML

Prescription type:

Prescription

Therapeutic area:

NEUROMUSCULAR BLOCKING AGENTS

Product summary:

Active ingredient group (AIG) number: 0118000001; AHFS:

Authorization status:

CANCELLED POST MARKET

Authorization date:

2008-02-15

Summary of Product characteristics

PRODUCT MONOGRAPH
PR
VECURONIUM BROMIDE FOR INJECTION
NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT
Pharmaceutical Partners of Canada Inc.
Date of Preparation:
45 Vogell Road, Suite 200
January 15, 2008
Richmond Hill, ON L4B 3P6
Control No.: 119276
Vecuronium Bromide for Injection, Product Monograph
Page 2 of 28
PRODUCT MONOGRAPH
PR
VECURONIUM BROMIDE FOR INJECTION
NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT
THIS DRUG SHOULD BE ADMINISTERED ONLY BY
ADEQUATELY TRAINED INDIVIDUALS FAMILIAR WITH ITS
ACTIONS, CHARACTERISTICS AND HAZARDS
ACTIONS AND CLINICAL PHARMACOLOGY
Vecuronium Bromide for Injection is a non-depolarizing neuromuscular
blocking agent of
intermediate duration possessing all of the characteristic
pharmacological actions of this class of
drugs (curariform). It acts by competing for cholinergic receptors at
the motor end-plate. The
antagonism
to
acetylcholine
is
inhibited
and
neuromuscular
block
reversed
by
acetylcholinesterase inhibitors such as neostigmine. Vecuronium
Bromide for Injection is about
1/3 more potent than pancuronium; the duration of neuromuscular
blockade produced by
Vecuronium Bromide for Injection is shorter than that of pancuronium
at initially equipotent
doses. The time to onset of paralysis decreases and the duration of
maximum effect increases
with
increasing
Vecuronium
Bromide
for
Injection
doses.
The
use
of
a
peripheral
nerve
stimulator is of benefit in assessing the degree of muscular
relaxation.
The ED
90
(dose required to produce 90% suppression of the muscle twitch
response with
balanced anesthesia) has averaged 0.057 mg/kg (0.049 to 0.062 mg/kg in
various studies). An
initial Vecuronium Bromide for Injection dose of 0.08 to 0.10 mg/kg
generally produces first
depression of twitch in approximately 1 minute, good or excellent
intubation conditions within
2.5 to 3 minutes, and maximum neuromuscular blockade within 3 to 5
minutes of injection in
Vecuronium Bromide for Injection, Product Monograph
Page 3 of 28
most patients. After the administration of an in